Immunocore Holdings plc

Immunocore is a commercial-stage biotechnology company that develops a novel class of T cell receptor (TCR) bispecific immunotherapies called ImmTAX (Immune mobilizing monoclonal TCRs Against X disease), designed to treat cancer, autoimmune diseases, and infectious diseases. The company's proprietary platform generates three types of bispecific molecules: ImmTAC for cancer, ImmTAV for infectious diseases (particularly HIV), and ImmTAAI for autoimmune diseases (targeting tissue-specific immune modulation). Its lead commercial product, KIMMTRAK (tebentafusp), is approved in 39 countries for HLA-A*02:01-positive unresectable or metastatic uveal melanoma — a rare, aggressive eye cancer that previously had no approved treatment. KIMMTRAK is the standard of care in all major markets where it is launched. The company's pipeline includes brenetafusp, a PRAME-targeting ImmTAC candidate in Phase 3 for first-line advanced cutaneous melanoma, tebentafusp in Phase 3 for second-line cutaneous melanoma (TEBE-AM) and adjuvant uveal melanoma (ATOM), IMC-M113V for HIV functional cure, and IMC-S118AI for type 1 diabetes. The company trades on Nasdaq under the ticker IMCR. Updated Aug 6, 2026